Kite, a Gilead Company, presents long-term CAR T cell therap

Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting Primary analysis of pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphomaLong-term overall survival and safety management data...

Related Keywords

Australia , United States , Canada , How Long , New South Wales , Caron Jacobson , Tom Van Meerten , Dick Sundh , Fred Locke , Cressida Robson , Patrick Johnston , Axicabtagene Ciloleucel , Olalekan Oluwole , Mahmoud Elsawy , Dominique Tonelli , Head Of Medical Affairs , Health Economics , Gilead Company , European Society For Blood , Outcomes Research , European Society , Marrow Transplantation , Annual Meeting , Vice President , Session Number , Patients With , Indolent Non Hodgkin Lymphoma , Corticosteroid Use With Axicabtagene Ciloleucel , Refractory Largeb Cell Lymphoma , Largeb Cell Lymphoma , Versus Standard Of Care , Therapy In Patients With , Refractory Largeb Cell , Reported Outcomes , Year Overall , Pivotal Study , Patients With Refractory Largeb Cell Lymphoma , The United , Executive Director , Medical Affairs ,